Neos Therapeutics, Inc.
(NASDAQ : NEOS)

( )
NEOS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
4.81%16.122.0%$220.21m
SHPGShire PLC Sponsored ADR
-0.43%180.080.4%$214.20m
PRGOPerrigo Co. Plc
-2.94%63.476.8%$106.37m
JAZZJazz Pharmaceuticals Plc
-5.91%141.792.2%$102.24m
ENDPEndo International Plc
-4.51%12.918.9%$68.26m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-2.22%129.256.3%$64.77m
MNKMallinckrodt Plc
-0.52%30.9121.1%$56.81m
SAGESAGE Therapeutics, Inc.
-0.90%108.059.6%$54.08m
ICPTIntercept Pharmaceuticals, Inc.
-4.15%96.5318.7%$48.16m
HZNPHorizon Pharma plc
-2.79%21.247.4%$47.64m
UTHRUnited Therapeutics Corporation
-1.55%110.9714.4%$43.54m
CTLTCatalent Inc
-0.84%37.902.4%$38.09m
PTLAPortola Pharmaceuticals, Inc.
-4.48%19.187.7%$34.63m
ICLRICON Plc
-1.62%135.764.1%$33.24m
AERIAerie Pharmaceuticals, Inc.
-4.43%41.406.9%$28.35m

Company Profile

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30,1994 and is headquartered in Grand Prairie, TX.